EXecutive: XIENCE V Everolimus Eluting Coronary Stent System (XIENCE V EECSS) in the Treatment of the Specific Setting of Patients With Multi-Vessel Coronary Artery Disease.

Trial Profile

EXecutive: XIENCE V Everolimus Eluting Coronary Stent System (XIENCE V EECSS) in the Treatment of the Specific Setting of Patients With Multi-Vessel Coronary Artery Disease.

Completed
Phase of Trial: Phase IV

Latest Information Update: 08 May 2013

At a glance

  • Drugs Everolimus; Paclitaxel
  • Indications Coronary artery disease; Coronary artery restenosis; Myocardial ischaemia
  • Focus Therapeutic Use
  • Acronyms EXecutive
  • Sponsors Abbott Laboratories
  • Most Recent Events

    • 10 Mar 2010 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
    • 18 Sep 2009 Planned end date changed from 1 Sep 2011 to 1 Oct 2012 as reported by ClinicalTrials.gov.
    • 03 Jan 2008 Added trial centre from NCT last updated 3 Jan 2008.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top